Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06084013 · ClinicalTrials.gov registry record
Use Of Indocyanine Green In Pancreas Surgery
A clinical trial of Pancreatic Carcinoma, sponsored by OHSU Knight Cancer Institute.
- Recruiting
- Registry status
- 55
- Enrollment target
- 1
- Study location
NCT06084013: Recruiting study of Pancreatic Carcinoma, sponsored by OHSU Knight Cancer Institute.
NCT06084013 is a study of Pancreatic Carcinoma that is actively recruiting participants, run by OHSU Knight Cancer Institute. The registered enrollment target is 55 participants, below the 3,482-participant average among 18 other Pancreatic Carcinoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06084013, a study of Pancreatic Carcinoma, is actively recruiting participants, sponsored by OHSU Knight Cancer Institute.
- RECRUITING
- Registry status
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the use of indocyanine green to predict postoperative pancreatic leaks in patients undergoing transection of the pancreas.
Primary Outcome
Measurement of drain fluid amylase in post operative period. Defined by definitions of the International Study Group on Pancreatic Surgery (ISGPS) criteria
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2024-05-17 |
| Est. Completion | 2026-02-28 |
What NCT06084013 shows while recruiting
NCT06084013 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 3,482-participant average among 18 other Pancreatic Carcinoma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Pancreatic Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06084013 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT06084013 about?
NCT06084013 is a clinical study titled "Use Of Indocyanine Green In Pancreas Surgery". This study evaluates the use of indocyanine green to predict postoperative pancreatic leaks in patients undergoing transection of the pancreas.
What is the current status of trial NCT06084013?
This trial is currently recruiting. The enrollment target is 55 participants. The study started on 2024-05-17. Estimated completion is 2026-02-28.
What conditions does trial NCT06084013 study?
This clinical trial studies the following conditions: Pancreatic Carcinoma.
What interventions are being tested in trial NCT06084013?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06084013?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06084013 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06084013's enrollment target sits among peer trials
55 11th of 18 higher than 8 of 18 other Pancreatic Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
RECRUITING · Phase 3
-
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
RECRUITING
-
Pilot Study of Pancreatic Cancer Screening
RECRUITING
-
A Study of MGC028 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Pancreatic Cancer Detection Consortium
RECRUITING
-
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI